Alto Neuroscience, Inc. - 8-K Filing
Alto Neuroscience reported Q1 2026 financial results with cash balance increasing to $264 million following a $120 million PIPE in March 2026, which is expected to fund operations through 2029. The company initiated its Phase 2b trial of ALTO-207 for treatment-resistant depression and reported new analyses supporting potential cognitive benefits from ALTO-101. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ANRO